Institut Jantung Negara | Clinical Research Department

Research site

(Unclaimed)

Location

145 Jalan Tun Razak, Kuala Lumpur, Selangor, Malaysia

Site insights

Top conditions

Top treatments

Macitentan

Pradaxa

Vicadrostat

JNJ-67896049

Aspirin

BI 690517

Rocuronium

Milvexian

Thienopyridine

Vitamin K

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 40 total trials

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Enrolling

Acute Coronary Syndrome

Drug: Milvexian

Other: Placebo

Locations recently updated

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation (LIBREXIA-AF)

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Active, not recruiting

Atrial Fibrillation

Drug: Apixaban Placebo

Drug: Milvexian

A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) (TOMORROW)

This is a prospective, multicenter, open-label, randomized, controlled, parallel Phase 3 study with an open-label single-arm extension period to eval...

Active, not recruiting

Pulmonary Arterial Hypertension

Drug: Macitentan

Other: Standard-of-care

A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these cond...

Enrolling

Hypertension

Cardiovascular Diseases

Drug: Placebo matching Vicadrostat

Drug: Vicadrostat

Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents Versus Everolimus-Eluting Stents in Coronary Artery Disease Patients With Diabetes Mellitus Global (ABILITY)

To compare in diabetic patients eligible for percutaneous coronary intervention (PCI) with minimal exclusion criteria, the efficacy and safety of Abl...

Active, not recruiting

Coronary Artery Disease

Diabetes

Device: XIENCE Everolimus Eluting Coronary Stent System (XIENCE family)

Device: Abluminus DES+ Sirolimus Eluting Stent System (SES)

Safety & Efficacy of RenalGuard® Therapy in the Prevention of Cardiac Surgery Associated Acute Kidney Injury (SAFEGUARD)

The goal of this clinical trial is to assess the effect of RenalGuard Therapy in reducing the rates of Acute Kidney Injury (AKI) within 72 hours afte...

Begins enrollment this month

Cardiac Surgery Associated - Acute Kidney Injury

AKI - Acute Kidney Injury

Device: RenalGuard® Therapy

Other: Standard of Care (SOC)